Literature DB >> 26377391

Factors affecting recurrence and prognosis after R0 resection for colorectal cancer with peritoneal metastasis.

Harunobu Sato1, Koutaro Maeda2, Kenjiro Kotake3, Kenichi Sugihara4, Hiroshi Takahashi5.   

Abstract

BACKGROUND: Peritoneal metastases (PM) are a well-known poor prognostic factor. The aim of this study was to investigate the factors affecting recurrence and prognosis after R0 resection for colorectal cancer with synchronous peritoneal metastases.
METHODS: We conducted a multi-institutional retrospective analysis of 72 patients without distant metastases who underwent R0 surgery between 1991 and 2007 for colorectal cancer with PM localized to the adjacent peritoneum. Clinicopathological variables were analyzed for their significance to recurrence and prognosis.
RESULTS: Recurrence was found in 51 patients (70.8%) after R0 surgery. In logistic regression analyses, lymph node metastasis was shown to be an independent factor affecting recurrence. Non-intensive or no postoperative chemotherapy and eight or fewer dissected lymph nodes were identified as independent poor prognostic factors using the Cox proportional hazards model. Among patients who received postoperative chemotherapy, prognosis was significantly better in those who received intensive adjuvant chemotherapy using camptothecin-11 or oxaliplatin after R0 surgery than in those who received non-intensive chemotherapy. Among 47 patients whose recurrence date was known, 33 patients (70.2%) experienced recurrence within 18 months after R0 surgery for peritoneal metastases, and hematogenous recurrence was observed significantly more often than peritoneal recurrence.
CONCLUSIONS: Harvesting of more than eight lymph nodes and administration of intense adjuvant chemotherapy after R0 surgery are recommended for greater prediction accuracy and improved prognosis. Intensive follow-up should be performed within 18 months after R0 surgery for colorectal cancer with synchronous peritoneal metastases.

Entities:  

Keywords:  Colorectal cancer; Peritoneal metastases; Prognosis; R0 surgery; Recurrence

Mesh:

Year:  2015        PMID: 26377391     DOI: 10.1007/s00535-015-1122-8

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  26 in total

1.  Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

Authors:  Jan Franko; Qian Shi; Charles D Goldman; Barbara A Pockaj; Garth D Nelson; Richard M Goldberg; Henry C Pitot; Axel Grothey; Steven R Alberts; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management.

Authors:  S R Pestieau; P H Sugarbaker
Journal:  Dis Colon Rectum       Date:  2000-10       Impact factor: 4.585

3.  Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis.

Authors:  Jan Franko; Zuhaib Ibrahim; Niraj J Gusani; Matthew P Holtzman; David L Bartlett; Herbert J Zeh
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

4.  Enhancing the objectivity of the Japanese classification of peritoneal metastases from colorectal cancer.

Authors:  Hirotoshi Kobayashi; Kenjiro Kotake; Kenichi Sugihara
Journal:  Jpn J Clin Oncol       Date:  2014-08-18       Impact factor: 3.019

5.  Validation and clinical use of the Japanese classification of colorectal carcinomatosis: benefit of surgical cytoreduction even without hyperthermic intraperitoneal chemotherapy.

Authors:  Hirotoshi Kobayashi; Masayuki Enomoto; Tetsuro Higuchi; Hiroyuki Uetake; Satoru Iida; Toshiaki Ishikawa; Megumi Ishiguro; Kenichi Sugihara
Journal:  Dig Surg       Date:  2010-11-10       Impact factor: 2.588

6.  Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.

Authors:  Gunnar Folprecht; Thomas Gruenberger; Wolf O Bechstein; Hans-Rudolf Raab; Florian Lordick; Jörg T Hartmann; Hauke Lang; Andrea Frilling; Jan Stoehlmacher; Jürgen Weitz; Ralf Konopke; Christian Stroszczynski; Torsten Liersch; Detlev Ockert; Thomas Herrmann; Eray Goekkurt; Fabio Parisi; Claus-Henning Köhne
Journal:  Lancet Oncol       Date:  2009-11-26       Impact factor: 41.316

7.  Survival benefit of repeat liver resections for recurrent colorectal metastases: 143 cases. Association Francaise de Chirurgie.

Authors:  B Nordlinger; J C Vaillant; M Guiguet; P Balladur; F Paris; P Bachellier; D Jaeck
Journal:  J Clin Oncol       Date:  1994-07       Impact factor: 44.544

8.  Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.

Authors:  Dominique Elias; Jérémie H Lefevre; Julie Chevalier; Antoine Brouquet; Frédéric Marchal; Jean-Marc Classe; Gwenaël Ferron; Jean-Marc Guilloit; Pierre Meeus; Diane Goéré; Julia Bonastre
Journal:  J Clin Oncol       Date:  2008-12-22       Impact factor: 44.544

9.  Prognostic factors in patients with synchronous peritoneal carcinomatosis (PC) caused by a primary cancer of the colon.

Authors:  Sotaro Sadahiro; Toshiyuki Suzuki; Yuji Maeda; Akira Tanaka; Hiroyasu Makuuchi; Akemi Kamijo; Yasuo Haruki; Chieko Murayama
Journal:  J Gastrointest Surg       Date:  2009-06-02       Impact factor: 3.452

10.  Factors influencing the natural history of colorectal liver metastases.

Authors:  R Stangl; A Altendorf-Hofmann; R M Charnley; J Scheele
Journal:  Lancet       Date:  1994-06-04       Impact factor: 79.321

View more
  4 in total

1.  Clinical outcomes of stage IV colorectal cancer after R0 resection: a multi-institutional retrospective analysis.

Authors:  Harunobu Sato; Koutarou Maeda; Zenichi Morise; Hiroshi Takahashi; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2016-10-06       Impact factor: 3.402

2.  Factors affecting R0 resection of colorectal cancer with synchronous peritoneal metastases: a multicenter prospective observational study by the Japanese Society for Cancer of the Colon and Rectum.

Authors:  Dai Shida; Hirotoshi Kobayashi; Masao Kameyama; Kazuo Hase; Kotaro Maeda; Takeshi Suto; Michio Itabashi; Kimihiko Funahashi; Fumikazu Koyama; Heita Ozawa; Shingo Noura; Hideyuki Ishida; Yukihide Kanemitsu; Kenjiro Kotake; Kenichi Sugihara
Journal:  Int J Clin Oncol       Date:  2019-11-01       Impact factor: 3.402

3.  Overall survival after recurrence in stage I-III colorectal cancer patients in accordance with the recurrence organ site and pattern.

Authors:  Hiroshi Sawayama; Yuji Miyamoto; Yukiharu Hiyoshi; Katsuhiro Ogawa; Rikako Kato; Takahiko Akiyama; Yuki Kiyozumi; Naoya Yoshida; Hideo Baba
Journal:  Ann Gastroenterol Surg       Date:  2021-07-14

Review 4.  FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors.

Authors:  Tianshuo Yang; Long Ma; Haodong Hou; Feng Gao; Weijing Tao
Journal:  Front Oncol       Date:  2022-01-04       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.